Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $34.00 price target on the stock.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at JPMorgan Chase & Co. from $26.00 to $30.00. They now have an "overweight" rating on the stock.
Analyst Estimates: Here's What Brokers Think Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) After Its First-Quarter Report [Yahoo! Finance]
Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at Evercore ISI from $25.00 to $30.00. They now have an "outperform" rating on the stock.